Literature DB >> 29276049

Dengvaxia: age as surrogate for serostatus.

Maíra Aguiar1, Nico Stollenwerk2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29276049     DOI： 10.1016/S1473-3099(17)30752-1

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  8 in total

1.  Time-dependent force of infection and effective reproduction ratio in an age-structure dengue transmission model in Bandung City, Indonesia.

Authors:  Juni Wijayanti Puspita; Muhammad Fakhruddin; Nuning Nuraini; Edy Soewono
Journal:  Infect Dis Model       Date:  2022-07-11

2.  Modeling the initial phase of COVID-19 epidemic: The role of age and disease severity in the Basque Country, Spain.

Authors:  Akhil Kumar Srivasrav; Nico Stollenwerk; Joseba Bidaurrazaga Van-Dierdonck; Javier Mar; Oliver Ibarrondo; Maíra Aguiar
Journal:  PLoS One       Date:  2022-07-13       Impact factor: 3.752

3.  The role of mild and asymptomatic infections on COVID-19 vaccines performance: A modeling study.

Authors:  Maíra Aguiar; Joseba Bidaurrazaga Van-Dierdonck; Javier Mar; Nico Stollenwerk
Journal:  J Adv Res       Date:  2021-11-16       Impact factor: 12.822

4.  A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III.

Authors:  Dan Hu; Zhongyu Zhu; Shun Li; Yongqiang Deng; Yanling Wu; Nana Zhang; Vinita Puri; Chunyu Wang; Peng Zou; Cheng Lei; Xiaolong Tian; Yulu Wang; Qi Zhao; Wei Li; Ponraj Prabakaran; Yang Feng; Jane Cardosa; Chengfeng Qin; Xiaohui Zhou; Dimiter S Dimitrov; Tianlei Ying
Journal:  PLoS Pathog       Date:  2019-06-26       Impact factor: 6.823

Review 5.  Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines.

Authors:  Jue Hou; Weijian Ye; Jianzhu Chen
Journal:  Front Immunol       Date:  2022-02-24       Impact factor: 7.561

Review 6.  Intrinsic ADE: The Dark Side of Antibody Dependent Enhancement During Dengue Infection.

Authors:  Rohan Narayan; Shashank Tripathi
Journal:  Front Cell Infect Microbiol       Date:  2020-10-02       Impact factor: 5.293

7.  The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study.

Authors:  Maíra Aguiar; Nico Stollenwerk
Journal:  Vaccines (Basel)       Date:  2020-11-12

8.  Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data.

Authors:  Daniel J Laydon; Ilaria Dorigatti; Wes R Hinsley; Gemma Nedjati-Gilani; Laurent Coudeville; Neil M Ferguson
Journal:  Elife       Date:  2021-07-02       Impact factor: 8.140
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.